Induction with D-VRD and Autologous Hematopoietic Cell Transplantation in Patients Aged 70 and Older
Overview
This study evaluates the outcomes of newly diagnosed multiple myeloma patients aged 70 and older treated with D-VRD induction followed by autologous hematopoietic cell transplantation (autoHCT). The findings suggest comparable safety and efficacy between older and younger patients.
Background
Multiple myeloma is frequently diagnosed in older adults, yet clinical trials often exclude this age group, limiting the applicability of findings. The addition of daratumumab to induction regimens has shown improved outcomes in younger populations, but data on older patients remain scarce. This study aims to fill that gap by assessing the effectiveness of D-VRD induction in patients aged 70 and older.
Data Highlights
Characteristic
Older Group (≥70 years)
Younger Group (<70 years)
Median Age
74 (70–78)
59 (40–69)
Pre-transplant ≥VGPR
81% (22/27)
78% (76/98)
Post-transplant ≥VGPR
96% (26/27)
94% (92/98)
MRD Negativity Pre-transplant
42% (11/26)
49% (47/96)
Median PFS
36.5 months
Not specified
Key Findings
No non-relapse mortality events were reported in either age group.
Pre-transplant response rates were similar: ≥VGPR in 81% of older vs 78% of younger patients.
Post-transplant, ≥VGPR was observed in 96% of older vs 94% of younger patients.
Median time to neutrophil engraftment was 12 days in both age groups.
Median follow-up was 19.1 months, with 15.0 months for older patients.
Clinical Implications
The findings indicate that D-VRD induction followed by autoHCT is a viable treatment option for older patients with multiple myeloma, showing comparable efficacy to younger cohorts. Clinicians may consider this approach in managing newly diagnosed myeloma in older adults.
Conclusion
This study provides important insights into the treatment of older patients with multiple myeloma, demonstrating that D-VRD induction followed by autoHCT can achieve favorable outcomes similar to those seen in younger patients.
by Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Mark R. Tanner, Muhammad Bilal Islam, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Asad A. Haider, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
